Enlivex Therapeutics Ltd.(ENLV)

Biotechnology · Ness Ziona, TA

$0.35-0.01 (-2.98%)

Delayed quote: Oct 6, 2026, 12:19 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T16:22:03.098Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:22:03.098Z.

Quote observation: 2026-10-06T16:19:50.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 5,911,404
Total debt · period ending 2026-06-30: 17,248,000
Cash · period ending 2026-06-30: 5,518,000
TTM operating income · period ending 2026-06-30: -20,564,000

FMP input reference: 16b0ce149acf027305ec47ed69e441f7c4eae43bc3095c7aeda967d53938ba16

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ENLV EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

ENLV Competitors' EV/EBIT Ratio

ENLV

Enlivex Therapeutics Ltd.

Current

Market Cap

$5.91M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LUCY

Lucyd, Inc

vs ENLV

Market Cap

$5.85M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CDIO

Cardio Diagnostics Holdings, Inc.

vs ENLV

Market Cap

$6.02M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares

vs ENLV

Market Cap

$5.77M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SCNX

Scienture Holdings, Inc.

vs ENLV

Market Cap

$6.10M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACXP

Acurx Pharmaceuticals, Inc.

vs ENLV

Market Cap

$5.63M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NVNO

enVVeno Medical Corporation

vs ENLV

Market Cap

$5.60M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FEMY

Femasys Inc.

vs ENLV

Market Cap

$6.31M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENSC

Ensysce Biosciences, Inc.

vs ENLV

Market Cap

$6.39M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BMRA

Biomerica, Inc.

vs ENLV

Market Cap

$6.54M

EV/EBIT Ratio

N/A

TTM Avg

471.11x

3Y Avg

281.60x

5Y Avg

221.14x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Enlivex Therapeutics Ltd. (ENLV)	$5.91M	N/A	N/A	N/A	N/A
Lucyd, Inc (LUCY)vs ›	$5.85M	N/A	N/A	N/A	N/A
Cardio Diagnostics Holdings, Inc. (CDIO)vs ›	$6.02M	N/A	N/A	N/A	N/A
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs ›	$5.77M	N/A	N/A	N/A	N/A
Scienture Holdings, Inc. (SCNX)vs ›	$6.10M	N/A	N/A	N/A	N/A
Acurx Pharmaceuticals, Inc. (ACXP)vs ›	$5.63M	N/A	N/A	N/A	N/A
enVVeno Medical Corporation (NVNO)vs ›	$5.60M	N/A	N/A	N/A	N/A
Femasys Inc. (FEMY)vs ›	$6.31M	N/A	N/A	N/A	N/A
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.39M	N/A	N/A	N/A	N/A
Biomerica, Inc. (BMRA)vs ›	$6.54M	N/A	471.11x	281.60x	221.14x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

ENLV EV/EBIT Ratio Metrics

ENLV Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics